Relationship between requirement to stop during a six-minute walk test and health-related quality of life, physical activity and physical performance amongst people with intermittent claudication

Single-centre, double-blinded, randomised placebo-controlled trial to determine the effect of a 12-week home-based programme of footplate neuromuscular electrical stimulation on walking capacity in people with peripheral artery disease: a protocol for the Foot-PAD trial

INTRODUCTION

Patients with peripheral artery disease (PAD) can experience intermittent claudication, which limits walking capacity and the ability to undertake daily activities. While exercise therapy is an established way to improve walking capacity in people with PAD, it is not feasible in all patients. Neuromuscular electrical stimulation (NMES) provides a way to passively induce repeated muscle contractions and has been widely used as a therapy for chronic conditions that limit functional capacity. Preliminary trials in patients with PAD demonstrate that stimulation of the leg muscles using a footplate-NMES device can be performed without pain and may lead to significant gains in walking capacity. Studies, to date, have been small and have not been adequately controlled to account for any potential placebo effect. Therefore, the current trial will compare the effect of a 12-week programme of footplate-NMES with a placebo-control on walking capacity (6 min walking distance) and other secondary outcomes in patients with PAD.

METHODS AND ANALYSIS

The Foot-PAD trial is a double-blinded, randomised placebo-controlled trial to determine the effect of a 12-week home-based programme of footplate NMES on walking capacity in people with PAD. This is a single-centre trial with numerous recruitment locations. A total of 180 participants with stable PAD and intermittent claudication will be randomly assigned (1:1 ratio) to receive either footplate-NMES (intervention condition) or footplate-placebo (control condition) for two 30 min periods each day for 12 weeks. The footplate-NMES device will deliver stimulation sufficient to induce contraction of the leg muscles and repeated plantar and dorsiflexion at the ankles. The footplate-placebo device will deliver a momentary low-intensity transient stimulation that is insufficient to induce contraction of the leg muscles. Outcomes will be assessed at baseline (week 0), mid-intervention (week 6), postintervention (week 12) and 6 weeks after the completion of the intervention (week 18). The primary outcome is walking capacity at week 12, measured as maximum walking distance during the 6 min walk test. Secondary outcomes will include pain-free walking distance during the 6 min walk test; pain-free and maximum walking time during a graded treadmill walking test; disease-specific quality of life (Intermittent Claudication Questionnaire), self-reported walking impairment (Walking Impairment Questionnaire) and accelerometer-derived physical activity levels. Exploratory outcomes will include the Ankle-Brachial Index; leg vascular function; perception of device-use experience and symptom monitoring throughout the trial using the Claudication Symptom Instrument and a pain Visual Analogue Scale.

ETHICS AND DISSEMINATION

The Foot-PAD trial has received ethics approval from the Human Research Ethics Committees of Queensland Health Metro North Hospital and Health Service (78962) and the University of the Sunshine Coast (A21659). Regardless of the study outcomes, the study findings will be published in peer-reviewed scientific journals and presented at scientific meetings.

TRIAL REGISTRATION NUMBER

ACTRN12621001383853.

Sarcopenia is associated with lower step count in patients with peripheral artery disease following endovascular treatment

INTRODUCTION

Patients with peripheral artery disease (PAD) often complain of reduced physical activity (PA) despite improvements in intermittent claudication after successful endovascular treatment (EVT). Sarcopenia resulting from chronic ischemia can affect post-EVT PA levels.

OBJECTIVE

This study aims to assess the association between sarcopenia and post-EVT PA levels.

METHODS

One hundred five patients with PAD were consecutively enrolled in this study. PA was assessed using the post-EVT step count and the pre-EVT International Physical Activity Questionnaire. Sarcopenia was diagnosed based on the Asia Working Group for Sarcopenia and defined as low muscle mass and strength, and/or slow walking speed. The patients were categorized into three groups: 1) patients with sarcopenia (Sarcopenia Group); 2) patients with only low muscle mass or strength, and/or slow walking speed (Suspected-Sarcopenia Group); and 3) patients who did not fulfill all the sarcopenia criteria (No-Sarcopenia Group).

RESULTS

Proportions of patients in the Sarcopenia, Suspected-Sarcopenia, and No-Sarcopenia Groups were 31.4, 38.1, and 30.5%, respectively. After controlling for potential confounders, the Sarcopenia Group demonstrated significantly lower step counts than the Suspected-Sarcopenia Group (p = .016) and No-Sarcopenia Group (p = .009).

CONCLUSIONS

Our findings indicate that patients with PAD and sarcopenia require rehabilitation strategies to enhance physical performance.

Saving Legs & Lives: the efficacy of a community-based cardiovascular rehabilitation programme versus usual care on exercise capacity and quality of life in patients who have undergone lower limb revascularisation for peripheral arterial disease-protocol for a single-centre randomised-controlled trial

INTRODUCTION

Peripheral artery disease (PAD) is an atherosclerotic condition characterised by stenosis or occlusion of the arteries in the lower limbs. Patients with PAD commonly report intermittent claudication (leg pain/discomfort) during physical activities, which significantly limits the ability to walk and perform activities of daily living. Supervised exercise training is an effective therapy that can improve walking capacity in people with PAD. Emerging evidence also suggests that supervised exercise therapy following lower limb revascularisation can further enhance walking capacity when compared with revascularisation alone. However, access to dedicated exercise programmes for patients with PAD is limited in most countries, and there is a need to test the efficacy of alternative rehabilitation strategies and referral pathways. This randomised-controlled study aims to assess the efficacy of a cardiovascular rehabilitation (CR) programme versus usual care on walking capacity and quality of life in patients who have undergone lower limb revascularisation for PAD.

METHODS AND ANALYSIS

This will be a single-centre, prospective, parallel group, randomised-controlled trial. Sixty-six participants who have undergone a lower limb revascularisation procedure for PAD, in the previous 12 months, will be randomly allocated to a CR programme or a usual care (control) group. The CR programme will include two supervised exercise sessions per week for 6 weeks primarily consisting of intermittent treadmill walking at a moderate exercise intensity and home-based walking advice. During the 6-week programme, participants will also attend one education seminar (5.5 hours) which will cover topics such as diet, medications, exercise training and lifestyle modifications for the management of cardiovascular diseases. The control group will receive usual care and medical advice from their local doctor and vascular surgeon. The primary outcome will be 6-min walk distance. Secondary outcomes include pain-free walking distance during the six-minute walk test, maximal and pain-free walking time during a graded treadmill walking test, cardiorespiratory fitness, self-reported walking capacity, disease-specific quality of life, and self-reported and objectively measured physical activity levels. Exploratory outcomes include brachial artery flow-mediated dilation, arterial stiffness, ankle-brachial blood pressure index and biomarkers of cardiovascular disease risk. Outcomes will be assessed at baseline (week 1), following the CR/usual care period (week 8) and again at 6-month follow-up (week 34).

ETHICS AND DISSEMINATION

This study has received ethics approval from the Human Research Ethics Committees of Queensland Health Metro North Hospital and Health Service (94155) and the University of the Sunshine Coast (S231914). Findings from this study will be disseminated in peer-reviewed journals and through national and international conference presentations.

TRIAL REGISTRATION NUMBER

ACTRN12623000190606.

Determination of Treatment Efficacy after Revascularization of Intermittent Claudication Patients by Physical Function Assessment

PURPOSE

There have been few reports examining changes in physical activity (PA) after revascularization of lower extremities from the perspective of physical function at discharge. The purpose of this study was to clarify the effects of physical function before discharge on the amount of PA after discharge in patients who underwent revascularization.

METHODS

The subjects were 34 Fontaine class II patients admitted for elective surgical revascularization or endovascular treatment at two hospitals from September 2017 to October 2019. Triaxial accelerometers were used to measure changes in sedentary behavior (SB) before admission and 1 month after discharge. Multiple regression analysis was performed on the 6-min walking distance (6MWD) at the time of discharge and the change in SB 1 month after discharge; the cutoff value was calculated from the receiver operating characteristic (ROC) curve.

RESULTS

SB 1 month after discharge significantly decreased in the decreased SB group compared to the increased SB group (575.5 [400-745.2] vs. 649.5 [453.8-809.2], p <0.01). ROC curve was plotted with SB increase/decrease as the dependent variable and 6MWD at discharge as the independent variable; the cutoff value was 357.5 m.

CONCLUSION

6MWD measurement at discharge may help predict changes in SB after discharge.

Comparison of catheter ablation and medical therapy for atrial fibrillation in heart failure patients: A meta-analysis of randomized controlled trials

BACKGROUND

The results of studies comparing the outcomes of catheter ablation (CA) to those of medical therapy (MT) for atrial fibrillation (AF) in heart failure (HF) patients are contradictory.

OBJECTIVES

Our objective was to conduct a meta-analysis that included randomized controlled trials (RCTs) that compared these two therapy options for AF in HF patients.

METHODS

We searched PubMed, Google Scholar, and the Cochrane Library for eligible studies. After reviewing all potential studies, we conducted this meta-analysis with the remaining 10 RCTs. We used a modified Jadad scale to assess the publications' quality, and we used the Risk of Bias 2 tool to assess the RCTs' bias risk.

RESULTS

The meta-analysis comprised 2,187 patients. Patients treated with CA had a lower risk of all-cause mortality than patients treated with MT (RR=0.64 [0.5, 0.82]; p < 0.01). The CA group had greater improvement in left ventricular ejection fraction (LVEF) than the MT group (mean difference [MD]=5.38 [1.80, 8.97]; p < 0.01). Patients in the CA group had longer 6-min walking distances than patients in the MT group (MD=20.3 [-4.37, 44.9], p < 0.01). Compared to the MT group, the CAD group demonstrated a greater reduction in scores on the Minnesota Living with Heart Failure Questionnaire (MD= -9.59 [-16.72, -2.45], p < 0.01).

CONCLUSION

This meta-analysis highlights the importance of CA in terms of all-cause mortality and includes the highest number of patients of any study on this topic. Moreover, compared to MT, CA therapy is associated with greater improvements in LVEF and quality of life.

Health-related quality of life after a one-year follow-up of patients undergoing endovascular leg revascularization

BACKGROUND

Lower limb revascularization not only improves walking distance, but also disease-specific and general health-related quality of life (HRQoL). Therefore, we analyzed changes in HRQoL after endovascular leg revascularization in patients with chronic lower limb ischemia during a one-year follow-up.

PATIENTS AND METHODS

The WHOQOL-BREF questionnaire was completed by 50 patients with intermittent claudication (IC) and 50 patients with chronic limb-threatening ischemia (CLTI) who underwent endovascular revascularization with a stent implantation, as well as 40 patients with IC not requiring endovascular intervention who received medical management only. The survey was completed before and then 3 and 12 months after an intervention.

RESULTS

Patients with CLTI before endovascular intervention had the lowest HRQoL in the somatic, psychological, social, and environmental domains. After endovascular revascularization, these patients achieved the greatest improvement in HRQoL. Scores in the HRQoL domains correlated with Rutherford class, ankle-brachial index, and walking distance. The initial score in the somatic domain predicted the risk of target lesion revascularization (TLR) during the one-year follow-up.

CONCLUSIONS

Endovascular leg revascularization improved patients' functioning, not only in the physical, but also in the psychological, environmental and social domains of HRQoL. A higher score in the somatic domain of HRQoL before and at 3 months after an intervention predicted the risk of TLR during the one-year follow-up. It is recommended that scores for general HRQoL domains are added to the standard measures of the direct outcome of leg revascularization due to their one-year prognostic value.